The Medicare Payment Advisory Commission is rethinking how Medicare Part B should manage high-cost drugs approved through the US Food and Drug Administration’s accelerated approval pathway, informed by the Centers for Medicare and Medicaid Services’ recent experience with imposing coverage with evidence development (CED) requirements on such drugs.
MedPAC recommended in its June report that CMS should combine CED with Medicare payment caps to lower costs for certain...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?